Third-Line Treatment Options for HER2+ mBC after Progression on Trastuzumab Deruxtecan

Experts review the most recent data and discuss current strategies for the management of HR+ metastatic breast cancer.

Minh-Tri Nguyen, MD, spoke with CancerNetwork® about differences between time to treatment, socioeconomic status, and clinical outcomes in rural and urban patients with breast cancer.

Patritumab deruxtecan continues to yield positive efficacy in 2 early phase trials assessing the agent in patients with metastatic non–small cell lung cancer and breast cancer.

Experts from Emory Winship Cancer Institute discuss how the FDA approval of sacituzumab govitecan will impact the treatment of breast cancer.

Bria-IMT plus retifanlimab continues to show positive clinical outcomes in a small cohort of patients with advanced, metastatic breast cancer, according to data from a phase 1/2 trial.

The phase 3 TORCHLIGHT study, examining toripalimab and paclitaxel, has become the first study in China to achieve positive outcomes with immunotherapy for triple-negative breast cancer.